---
title: "CLDN18.2 targeting increases chemotherapy sensitivity in pancreatic and lung cancer models"
id: "pubmed-42772182"
canonical_url: "https://medichelpline.com/clinical-feed/pubmed-42772182"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "PubMed / NCBI"
source_url: "https://pubmed.ncbi.nlm.nih.gov/42772182/"
doi: "10.1016/j.bbrc.2026.154610"
published_at: "2026-10-29T00:00:00.000Z"
evidence_level: "Journal Article"
license: "CC-BY-NC-4.0 / Informational Use"
---
# CLDN18.2 targeting increases chemotherapy sensitivity in pancreatic and lung cancer models
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/pubmed-42772182
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** PubMed / NCBI
- **Source URL:** [Original Journal Publication](https://pubmed.ncbi.nlm.nih.gov/42772182/)
- **DOI:** [10.1016/j.bbrc.2026.154610](https://doi.org/10.1016%2Fj.bbrc.2026.154610)
- **Published At:** 2026-10-29T00:00:00.000Z
- **Evidence Rating:** Journal Article
## Executive GIST (TL;DR)
- Investigators reported that high **CLDN18.2** expression correlated with shorter overall survival in pancreatic adenocarcinoma according to the dataset examined. - The study team used CLDN18.2 knockdown in DAN-G cells; two independent siRNAs increased sensitivity to 5-fluorouracil. - Authors observed that the anti-CLDN18.2 antibody **TST001** potentiated cisplatin cytotoxicity in lung cancer patient-derived organoids. - CLDN18.2 knockdown reduced **SLC7A11** mRNA levels in the tested cells, and this coincided with increased sensitivity to Ras-selective lethal 3 (RSL3). - RSL3-driven membrane lipid peroxidation increased after CLDN18.2 silencing, consistent with altered ferroptosis-related responses. - Two antibodies, **TST001** and **IMAB362**, both lowered **SLC7A11** mRNA in gastric cancer lines reported (KATO III and NUGC4). - Confocal imaging indicated IMAB362 internalization with partial lysosomal localization in the cell models examined. - The investigators noted that reduced **SLC7A11** and altered lipid-peroxidation responses are possible contributors to chemosensitization, but the causal link to chemotherapy sensitization was not established by the data presented. - The abstract did not report detailed dosing regimens, exact experimental timelines, or full quantitative metrics; those methodological details were not available in the source abstract.
## Clinical Analysis & Structured Key Points
Clipboard, Search History, and several other advanced features are temporarily unavailable. [ Skip to main page content ](https://pubmed.ncbi.nlm.nih.gov/42772182/#article-details) ### NIH Websites Are Changing * [Get the Latest Updates and FAQs on the transition](https://www.nih.gov/web-modernization) * Per [Executive Order 14434](https://www.whitehouse.gov/presidential-actions/2026/09/inaugurating-the-era-of-super-intelligence/), federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition. ![U.S. flag](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png) An official website of the United States government Here's how you know ![Dot gov](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg) **The .gov means it’s official.** Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site. ![Https](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg) **The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. [ ![NIH NLM Logo](https://cdn.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg) ](https://www.ncbi.nlm.nih.gov/) [Log in](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42772182%2F) Show account info Close #### Account Logged in as: **username** * [Dashboard](https://www.ncbi.nlm.nih.gov/myncbi/) * [Publications](https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/) * [Account settings](https://www.ncbi.nlm.nih.gov/account/settings/) * [Log out](https://www.ncbi.nlm.nih.gov/account/signout/?back_url=https%3A//pubmed.ncbi.nlm.nih.gov/42772182/) [Access keys](https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys) [NCBI Homepage](https://www.ncbi.nlm.nih.gov) [MyNCBI Homepage](https://pubmed.ncbi.nlm.nih.gov/myncbi/) [Main Content](https://pubmed.ncbi.nlm.nih.gov/42772182/#maincontent) [Main Navigation](https://pubmed.ncbi.nlm.nih.gov/42772182/) [ ![pubmed logo](https://cdn.ncbi.nlm.nih.gov/pubmed/a447896c-976f-490b-b86b-2668b65114a8/core/images/pubmed-logo-blue.svg) ](https://pubmed.ncbi.nlm.nih.gov/) [ ](https://pubmed.ncbi.nlm.nih.gov/42772182/ "Show search bar") Search: [](https://pubmed.ncbi.nlm.nih.gov/42772182/ "Clear search input")Search [Advanced](https://pubmed.ncbi.nlm.nih.gov/advanced/) [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/clipboard/) [ User Guide ](https://pubmed.ncbi.nlm.nih.gov/help/) Save Email Send to * [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/42772182/) * [My Bibliography](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42772182%2F%23open-bibliography-panel) * [Collections](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42772182%2F%23open-collections-panel) * [Citation manager](https://pubmed.ncbi.nlm.nih.gov/42772182/) Display options Display options Format Abstract PubMed PMID ## Save citation to file Format: Summary (text) PubMed PMID Abstract (text) CSV Create file Cancel ## Email citation Email address has not been verified. Go to [ My NCBI account settings ](https://account.ncbi.nlm.nih.gov/settings/) to confirm your email and then refresh this page. To: Subject: Body: Format: Summary Summary (text) Abstract Abstract (text) MeSH and other data Send email Cancel ### Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42772182/) Add Cancel ### Add to My Bibliography * My Bibliography Unable to load your delegates due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42772182/) Add Cancel ## Your saved search Name of saved search: Search terms: [Test search terms](https://pubmed.ncbi.nlm.nih.gov/42772182/) Would you like email updates of new search results? Saved Search Alert Radio Buttons * Yes * No Email: ([change](https://www.ncbi.nlm.nih.gov/account/settings/)) Frequency: Monthly Weekly Daily Which day? The first Sunday The first Monday The first Tuesday The first Wednesday The first Thursday The first Friday The first Saturday The first day The first weekday Which day? Sunday Monday Tuesday Wednesday Thursday Friday Saturday Report format: Summary Summary (text) Abstract Abstract (text) PubMed Send at most: 1 item 5 items 10 items 20 items 50 items 100 items 200 items Send even when there aren't any new results Optional text in email: Save Cancel ## Create a file for external citation management software Create file Cancel ## Your RSS Feed Name of RSS Feed: Number of items displayed: 5 10 15 20 50 100 Create RSS Cancel RSS Link Copy ### Full text links [![Elsevier Science full text link](https://cdn.ncbi.nlm.nih.gov/corehtml/query/egifs/https:--linkinghub.elsevier.com-ihub-images-PubMedLink.gif) Elsevier Science ](https://linkinghub.elsevier.com/retrieve/pii/S0006-291X\(26\)01376-8 "See full text options at Elsevier Science") [ Full text links ](https://pubmed.ncbi.nlm.nih.gov/42772182/) ### Actions Cite Collections Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42772182/) Add Cancel Permalink Permalink Copy Display options Display options Format Abstract PubMed PMID ### Experimental Resource Linked Discoveries ### Page navigation * [ Title & authors ](https://pubmed.ncbi.nlm.nih.gov/42772182/#heading) * [ Abstract ](https://pubmed.ncbi.nlm.nih.gov/42772182/#abstract) * [ Conflict of interest statement ](https://pubmed.ncbi.nlm.nih.gov/42772182/#conflict-of-interest) * [Similar articles](https://pubmed.ncbi.nlm.nih.gov/42772182/#similar) * [ MeSH terms ](https://pubmed.ncbi.nlm.nih.gov/42772182/#mesh-terms) * [ Substances ](https://pubmed.ncbi.nlm.nih.gov/42772182/#substances) * [Related information](https://pubmed.ncbi.nlm.nih.gov/42772182/#related-links) * [ LinkOut - more resources ](https://pubmed.ncbi.nlm.nih.gov/42772182/#linkout) Title & authors Abstract Conflict of interest statement Similar articles MeSH terms Substances Related information LinkOut - more resources Biochem Biophys Res Commun Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Biochem+Biophys+Res+Commun%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Biochem+Biophys+Res+Commun%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42772182/) . 2026 Oct 29:837:154610. doi: 10.1016/j.bbrc.2026.154610. Epub 2026 Sep 18. # CLDN18.2 targeting enhances chemotherapy sensitivity in pancreatic cancer cells and lung cancer organoids [Zhaoyuan Zhang](https://pubmed.ncbi.nlm.nih.gov/?term=Zhang+Z&cauthor_id=42772182)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42772182/#full-view-affiliation-1 "College of Life Science, Nankai University, Tianjin, China; State Key Laboratory of Medicinal Chemical Biology, Nankai University, Tianjin, China."), [Jiaqi Fu](https://pubmed.ncbi.nlm.nih.gov/?term=Fu+J&cauthor_id=42772182)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42772182/#full-view-affiliation-2 "Beijing Institute of Biological Products Co., Ltd., Beijing, China; Institute of Molecular Biology, Nankai University, Tianjin, China."), [Xuemin Li](https://pubmed.ncbi.nlm.nih.gov/?term=Li+X&cauthor_id=42772182)[ 3 ](https://pubmed.ncbi.nlm.nih.gov/42772182/#full-view-affiliation-3 "Division of Medical Technology, Tianjin Medical University, Tianjin, China."), [Yi Yang](https://pubmed.ncbi.nlm.nih.gov/?term=Yang+Y&cauthor_id=42772182)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42772182/#full-view-affiliation-1 "College of Life Science, Nankai University, Tianjin, China; State Key Laboratory of Medicinal Chemical Biology, Nankai University, Tianjin, China."), [Zehan Li](https://pubmed.ncbi.nlm.nih.gov/?term=Li+Z&cauthor_id=42772182)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42772182/#full-view-affiliation-1 "College of Life Science, Nankai University, Tianjin, China; State Key Laboratory of Medicinal Chemical Biology, Nankai University, Tianjin, China."), [Yalu Wu](https://pubmed.ncbi.nlm.nih.gov/?term=Wu+Y&cauthor_id=42772182)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42772182/#full-view-affiliation-1 "College of Life Science, Nankai University, Tianjin, China; State Key Laboratory of Medicinal Chemical Biology, Nankai University, Tianjin, China."), [Zhongqian Yin](https://pubmed.ncbi.nlm.nih.gov/?term=Yin+Z&cauthor_id=42772182)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42772182/#full-view-affiliation-1 "College of Life Science, Nankai University, Tianjin, China; State Key Laboratory of Medicinal Chemical Biology, Nankai University, Tianjin, China."), [Junfeng Yu](https://pubmed.ncbi.nlm.nih.gov/?term=Yu+J&cauthor_id=42772182)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42772182/#full-view-affiliation-1 "College of Life Science, Nankai University, Tianjin, China; State Key Laboratory of Medicinal Chemical Biology, Nankai University, Tianjin, China."), [Hao Zheng](https://pubmed.ncbi.nlm.nih.gov/?term=Zheng+H&cauthor_id=42772182)[ 4 ](https://pubmed.ncbi.nlm.nih.gov/42772182/#full-view-affiliation-4 "College of Life Science, Nankai University, Tianjin, China. Electronic address: 13079903198@163.com."), [Guangtao Xiang](https://pubmed.ncbi.nlm.nih.gov/?term=Xiang+G&cauthor_id=42772182)[ 5 ](https://pubmed.ncbi.nlm.nih.gov/42772182/#full-view-affiliation-5 "College of Life Science, Nankai University, Tianjin, China; State Key Laboratory of Medicinal Chemical Biology, Nankai University, Tianjin, China. Electronic address: 9820250078@nankai.edu.cn.") Affiliations Expand ### Affiliations * 1 College of Life Science, Nankai University, Tianjin, China; State Key Laboratory of Medicinal Chemical Biology, Nankai University, Tianjin, China. * 2 Beijing Institute of Biological Products Co., Ltd., Beijing, China; Institute of Molecular Biology, Nankai University, Tianjin, China. * 3 Division of Medical Technology, Tianjin Medical University, Tianjin, China. * 4 College of Life Science, Nankai University, Tianjin, China. Electronic address: 13079903198@163.com. * 5 College of Life Science, Nankai University, Tianjin, China; State Key Laboratory of Medicinal Chemical Biology, Nankai University, Tianjin, China. Electronic address: 9820250078@nankai.edu.cn. * PMID: **42772182** * DOI: [ 10.1016/j.bbrc.2026.154610 ](https://doi.org/10.1016/j.bbrc.2026.154610) Item in Clipboard # CLDN18.2 targeting enhances chemotherapy sensitivity in pancreatic cancer cells and lung cancer organoids Zhaoyuan Zhang et al. Biochem Biophys Res Commun. 2026. Show details Display options Display options Format Abstract PubMed PMID Biochem Biophys Res Commun Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Biochem+Biophys+Res+Commun%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Biochem+Biophys+Res+Commun%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42772182/) . 2026 Oct 29:837:154610. doi: 10.1016/j.bbrc.2026.154610. Epub 2026 Sep 18. ### Authors [Zhaoyuan Zhang](https://pubmed.ncbi.nlm.nih.gov/?term=Zhang+Z&cauthor_id=42772182)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42772182/#short-view-affiliation-1 "College of Life Science, Nankai University, Tianjin, China; State Key Laboratory of Medicinal Chemical Biology, Nankai University, Tianjin, China."), [Jiaqi Fu](https://pubmed.ncbi.nlm.nih.gov/?term=Fu+J&cauthor_id=42772182)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42772182/#short-view-affiliation-2 "Beijing Institute of Biological Products Co., Ltd., Beijing, China; Institute of Molecular Biology, Nankai University, Tianjin, China."), [Xuemin Li](https://pubmed.ncbi.nlm.nih.gov/?term=Li+X&cauthor_id=42772182)[ 3 ](https://pubmed.ncbi.nlm.nih.gov/42772182/#short-view-affiliation-3 "Division of Medical Technology, Tianjin Medical University, Tianjin, China."), [Yi Yang](https://pubmed.ncbi.nlm.nih.gov/?term=Yang+Y&cauthor_id=42772182)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42772182/#short-view-affiliation-1 "College of Life Science, Nankai University, Tianjin, China; State Key Laboratory of Medicinal Chemical Biology, Nankai University, Tianjin, China."), [Zehan Li](https://pubmed.ncbi.nlm.nih.gov/?term=Li+Z&cauthor_id=42772182)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42772182/#short-view-affiliation-1 "College of Life Science, Nankai University, Tianjin, China; State Key Laboratory of Medicinal Chemical Biology, Nankai University, Tianjin, China."), [Yalu Wu](https://pubmed.ncbi.nlm.nih.gov/?term=Wu+Y&cauthor_id=42772182)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42772182/#short-view-affiliation-1 "College of Life Science, Nankai University, Tianjin, China; State Key Laboratory of Medicinal Chemical Biology, Nankai University, Tianjin, China."), [Zhongqian Yin](https://pubmed.ncbi.nlm.nih.gov/?term=Yin+Z&cauthor_id=42772182)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42772182/#short-view-affiliation-1 "College of Life Science, Nankai University, Tianjin, China; State Key Laboratory of Medicinal Chemical Biology, Nankai University, Tianjin, China."), [Junfeng Yu](https://pubmed.ncbi.nlm.nih.gov/?term=Yu+J&cauthor_id=42772182)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42772182/#short-view-affiliation-1 "College of Life Science, Nankai University, Tianjin, China; State Key Laboratory of Medicinal Chemical Biology, Nankai University, Tianjin, China."), [Hao Zheng](https://pubmed.ncbi.nlm.nih.gov/?term=Zheng+H&cauthor_id=42772182)[ 4 ](https://pubmed.ncbi.nlm.nih.gov/42772182/#short-view-affiliation-4 "College of Life Science, Nankai University, Tianjin, China. Electronic address: 13079903198@163.com."), [Guangtao Xiang](https://pubmed.ncbi.nlm.nih.gov/?term=Xiang+G&cauthor_id=42772182)[ 5 ](https://pubmed.ncbi.nlm.nih.gov/42772182/#short-view-affiliation-5 "College of Life Science, Nankai University, Tianjin, China; State Key Laboratory of Medicinal Chemical Biology, Nankai University, Tianjin, China. Electronic address: 9820250078@nankai.edu.cn.") ### Affiliations * 1 College of Life Science, Nankai University, Tianjin, China; State Key Laboratory of Medicinal Chemical Biology, Nankai University, Tianjin, China. * 2 Beijing Institute of Biological Products Co., Ltd., Beijing, China; Institute of Molecular Biology, Nankai University, Tianjin, China. * 3 Division of Medical Technology, Tianjin Medical University, Tianjin, China. * 4 College of Life Science, Nankai University, Tianjin, China. Electronic address: 13079903198@163.com. * 5 College of Life Science, Nankai University, Tianjin, China; State Key Laboratory of Medicinal Chemical Biology, Nankai University, Tianjin, China. Electronic address: 9820250078@nankai.edu.cn. * PMID: **42772182** * DOI: [ 10.1016/j.bbrc.2026.154610 ](https://doi.org/10.1016/j.bbrc.2026.154610) Item in Clipboard Full text links Cite Display options Display options Format Abstract PubMed PMID Linked Discoveries ## Abstract Claudin 18 isoform 2 (CLDN18.2) is a therapeutic target in solid tumors, but its contribution to chemotherapy response remains unclear. We examined whether CLDN18.2 targeting increases drug sensitivity and whether this is accompanied by changes in solute carrier family 7 member 11 (SLC7A11) expression. High CLDN18 expression was associated with shorter overall survival in pancreatic adenocarcinoma. In DAN-G cells, two independent CLDN18.2 siRNAs increased sensitivity to 5-fluorouracil. TST001 enhanced cisplatin-induced cytotoxicity in lung cancer patient-derived organoids. CLDN18.2 knockdown also reduced SLC7A11 mRNA, increased sensitivity to Ras-selective lethal 3 (RSL3), and increased RSL3-induced membrane lipid peroxidation. TST001 and IMAB362 reduced SLC7A11 mRNA, and TST001 increased RSL3 sensitivity in KATO III and NUGC4 cells. Confocal images were consistent with IMAB362 internalization and partial lysosomal localization. These findings support CLDN18.2 targeting as an approach to chemotherapy sensitization in the models tested. Reduced SLC7A11 expression and altered lipid-peroxidation responses are possible contributors, but their causal involvement in chemotherapy sensitization remains to be established. **Keywords:** Chemosensitization; Claudin18.2; Ferroptosis; SLC7A11; Tumor organoid. Copyright © 2026 Elsevier Inc. All rights reserved. [PubMed Disclaimer](https://pubmed.ncbi.nlm.nih.gov/disclaimer/) ## Conflict of interest statement Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. ## Similar articles * [ Glucose deprivation induces cisplatin resistance through upregulation of SLC7A11 (xCT) expression in endometrial cancer cells. ](https://pubmed.ncbi.nlm.nih.gov/40306166/) Aoyama K, Yoriki K, Aoki K, Okamura A, Tarumi Y, Kataoka H, Kokabu T, Mori T.Aoyama K, et al.Biochem Biophys Res Commun. 2025 Jun 20;766:151887. doi: 10.1016/j.bbrc.2025.151887. Epub 2025 Apr 23.Biochem Biophys Res Commun. 2025.PMID: 40306166 * [ TTP enhances the sensitivity of KRASG12C-mutated lung cancer cells to KRASG12C inhibitors by downregulating SLC7A11 and promoting ferroptosis. ](https://pubmed.ncbi.nlm.nih.gov/41232353/) Park KR, Le MX, Sul OJ, Jeon J, Kwon MS, Lee H, Ra SW, Kwon HN, Cho WJ, Park JW.Park KR, et al.Biomed Pharmacother. 2025 Dec;193:118772. doi: 10.1016/j.biopha.2025.118772. Epub 2025 Nov 15.Biomed Pharmacother. 2025.PMID: 41232353 * [ [Effect of SLC7A11 gene downregulation on the gefitinib resistance of lung adenocarcinoma PC9/GR cells and its mechanism]. ](https://pubmed.ncbi.nlm.nih.gov/37805442/) Jia YL, Zhao Y, Zhen SM, Cheng ZS, Zheng BY, Liu YP, Liu LH.Jia YL, et al.Zhonghua Zhong Liu Za Zhi. 2023 Sep 23;45(9):779-786. doi: 10.3760/cma.j.cn112152-20220715-00493.Zhonghua Zhong Liu Za Zhi. 2023.PMID: 37805442Chinese. * [ Efficacy and safety of anti-CLDN18.2 therapies in advanced or metastatic gastric, gastro-oesophageal junction, and oesophageal carcinomas with CLDN18.2 positivity: a systematic review and meta-analysis. ](https://pubmed.ncbi.nlm.nih.gov/41989337/) Zhang Y, Kao S, Li D, Yan C, Huang B, Fang H.Zhang Y, et al.Future Oncol. 2026 May;22(12):1439-1451. doi: 10.1080/14796694.2026.2659354. Epub 2026 Apr 16.Future Oncol. 2026.PMID: 41989337 * [ Emerging targets in gastric and pancreatic cancer: Focus on claudin 18.2. ](https://pubmed.ncbi.nlm.nih.gov/39637967/) Tojjari A, Idrissi YA, Saeed A.Tojjari A, et al.Cancer Lett. 2025 Feb 28;611:217362. doi: 10.1016/j.canlet.2024.217362. Epub 2024 Dec 3.Cancer Lett. 2025.PMID: 39637967Review. [ See all similar articles ](https://pubmed.ncbi.nlm.nih.gov/?linkname=pubmed_pubmed&from_uid=42772182) ## MeSH terms * Amino Acid Transport System y+ / genetics Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Amino+Acid+Transport+System+y%2B%2Fgenetics%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Amino+Acid+Transport+System+y%2B) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42772182/) * Amino Acid Transport System y+ / metabolism Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Amino+Acid+Transport+System+y%2B%2Fmetabolism%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https:/
## Related Clinical Research

- [Sex Differences in ICI Survival for Advanced NSCLC: Meta-analysis Findings](https://medichelpline.com/clinical-feed/plos-one-15-sex-difference-in-survival-benefits-of-immune-checkpoint-inhibitors-in-advanced.md)
- [Chromeno[8,7-d]oxazole Lead AT-11: A CDK16 Inhibitor with Improved Solubility and Antitumor Activi](https://medichelpline.com/clinical-feed/pubmed-42822357.md) (DOI: 10.1016/j.bioorg.2026.110559)
- [Perioperative ivonescimab ± chemotherapy Yields High MPR in Resectable NSCLC (Phase 2)](https://medichelpline.com/clinical-feed/nature-1-perioperative-ivonescimab-with-or-without-chemotherapy-in-resectable-non-small.md)
- [XDH and ITPA linked to prognosis and cisplatin response in NSCLC: integrated bioinformatics and la](https://medichelpline.com/clinical-feed/pubmed-42972208.md) (DOI: 10.1007/s10142-026-02100-x)
- [PD-L1 expression and survival in unresectable or recurrent gastric cancer treated with first-line](https://medichelpline.com/clinical-feed/british-journal-of-cancer-0-pd-l1-expression-and-survival-in-unresectable-recurrent-gastric-cancer-treated.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.